Personalis EPS - Earnings per Share 2018-2026 | PSNL
Personalis eps - earnings per share from 2018 to 2026. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Personalis Annual EPS | |
|---|---|
| 2025 | $-0.91 |
| 2024 | $-1.37 |
| 2023 | $-2.25 |
| 2022 | $-2.48 |
| 2021 | $-1.49 |
| 2020 | $-1.20 |
| 2019 | $-1.39 |
| 2018 | $-6.49 |
| 2017 | $-7.78 |
| Personalis Quarterly EPS | |
|---|---|
| 2026-06-30 | $-0.30 |
| 2026-03-31 | $-0.29 |
| 2025-12-31 | $-0.26 |
| 2025-09-30 | $-0.24 |
| 2025-06-30 | $-0.23 |
| 2025-03-31 | $-0.18 |
| 2024-12-31 | $-0.23 |
| 2024-09-30 | $-0.64 |
| 2024-06-30 | $-0.24 |
| 2024-03-31 | $-0.26 |
| 2023-12-31 | $-0.54 |
| 2023-09-30 | $-0.60 |
| 2023-06-30 | $-0.50 |
| 2023-03-31 | $-0.61 |
| 2022-12-31 | $-0.67 |
| 2022-09-30 | $-0.58 |
| 2022-06-30 | $-0.60 |
| 2022-03-31 | $-0.63 |
| 2021-12-31 | $-0.46 |
| 2021-09-30 | $-0.40 |
| 2021-06-30 | $-0.34 |
| 2021-03-31 | $-0.29 |
| 2020-12-31 | $-0.35 |
| 2020-09-30 | $-0.27 |
| 2020-06-30 | $-0.29 |
| 2020-03-31 | $-0.29 |
| 2019-12-31 | $1.56 |
| 2019-09-30 | $-0.22 |
| 2019-06-30 | $-0.89 |
| 2019-03-31 | $-1.84 |
| 2018-12-31 | $0.00 |
| 2018-09-30 | $-1.19 |
| 2018-06-30 | $-2.39 |
| 2017-12-31 | $0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |